Xanthine Oxidase Inhibition With Febuxostat Attenuates Systolic Overload-Induced Left Ventricular Hypertrophy and Dysfunction in Mice

Journal of Cardiac Failure

Volumn 14, Issue 9, 2008, Pages 746-753

  Xu, Xin ^a   Hu, Xinli ^a   Lu, Zhongbing ^a   Zhang, Ping ^a   Zhao, Lin ^b   Wessale, Jerry L ^b   Bache, Robert J ^a   Chen, Yingjie ^a  

^a Vascular Biology Center   (United States)

^b TAP PHARMACEUTICAL PRODUCTS INC   (United States)

Author keywords

Left ventricular dysfunction; myocardial hypertrophy; pressure overload; xanthine oxidase inhibition

Indexed keywords

3 NITROTYROSINE; FEBUXOSTAT; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; PROTEIN P42; PROTEIN P44; URIC ACID; XANTHINE OXIDASE;

ANIMAL TISSUE; AORTA CONSTRICTION; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; ECHOCARDIOGRAPHY; ENZYME INHIBITION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE CELL; HEART VENTRICLE OVERLOAD; MALE; MORTALITY; MOUSE; NONHUMAN; ORGAN WEIGHT; OXIDATIVE STRESS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANIMALS; DISEASE MODELS, ANIMAL; HYPERTROPHY, LEFT VENTRICULAR; MALE; MICE; MICE, INBRED C57BL; SYSTOLE; THIAZOLES; VENTRICULAR DYSFUNCTION, LEFT;

EID: 55149124723     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2008.06.006     Document Type: Article

References (35)

1. Parks D.A., and Granger D.N. Xanthine oxidase: biochemistry, distribution and physiology. Acta Physiol Scand Suppl 548 (1986) 87-99
2. de Jong J.W., van der Meer P., Nieukoop A.S., Huizer T., Stroeve R.J., and Bos E. Xanthine oxidoreductase activity in perfused hearts of various species, including humans. Circ Res 3 (1990) 770-773
3. Kittleson M.M., and Hare J.M. Xanthine oxidase inhibitors: an emerging class of drugs for heart failure. Eur Heart J 15 (2005) 1458-1460
4. Ekelund U.E., Harrison R.W., Shokek O., Thakkar R.N., Tunin R.S., Senzaki H., et al. Intravenous allopurinol decreases myocardial oxygen consumption and increases mechanical efficiency in dogs with pacing-induced heart failure. Circ Res 5 (1999) 437-445
5. Saavedra W.F., Paolocci N., St John M.E., Skaf M.W., Stewart G.C., Xie J.S., et al. Imbalance between xanthine oxidase and nitric oxide synthase signaling pathways underlies mechanoenergetic uncoupling in the failing heart. Circ Res 3 (2002) 297-304
6. Cappola T.P., Kass D.A., Nelson G.S., Berger R.D., Rosas G.O., Kobeissi Z.A., et al. Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy. Circulation 20 (2001) 2407-2411
7. Ukai T., Cheng C.P., Tachibana H., Igawa A., Zhang Z.S., Cheng H.J., et al. Allopurinol enhances the contractile response to dobutamine and exercise in dogs with pacing-induced heart failure. Circulation 5 (2001) 750-755
8. Amado L.C., Saliaris A.P., Raju S.V., Lehrke S., St John M., Xie J., et al. Xanthine oxidase inhibition ameliorates cardiovascular dysfunction in dogs with pacing-induced heart failure. J Mol Cell Cardiol 3 (2005) 531-536
9. Stull L.B., Leppo M.K., Szweda L., Gao W.D., and Marban E. Chronic treatment with allopurinol boosts survival and cardiac contractility in murine postischemic cardiomyopathy. Circ Res 10 (2004) 1005-1011
10. Engberding N., Spiekermann S., Schaefer A., Heineke A., Wiencke A., Muller M., et al. Allopurinol attenuates left ventricular remodeling and dysfunction after experimental myocardial infarction: a new action for an old drug?. Circulation 15 (2004) 2175-2179
11. Naumova A.V., Chacko V.P., Ouwerkerk R., Stull L., Marban E., and Weiss R.G. Xanthine oxidase inhibitors improve energetics and function after infarction in failing mouse hearts. Am J Physiol Heart Circ Physiol 2 (2006) H837-H843
12. Minhas K.M., Saraiva R.M., Schuleri K.H., Lehrke S., Zheng M., Saliaris A.P., et al. Xanthine oxidoreductase inhibition causes reverse remodeling in rats with dilated cardiomyopathy. Circ Res 2 (2006) 271-279
13. Takano Y., Hase-Aoki K., Horiuchi H., Zhao L., Kasahara Y., Kondo S., et al. Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase. Life Sci 16 (2005) 1835-1847
14. Hou M., Hu Q., Chen Y., Zhao L., Zhang J., and Bache R.J. Acute effects of febuxostat, a nonpurine selective inhibitor of xanthine oxidase, in pacing induced heart failure. J Cardiovasc Pharmacol 5 (2006) 255-263
15. Hu P., Zhang D., Swenson L., Chakrabarti G., Abel E.D., and Litwin S.E. Minimally invasive aortic banding in mice: effects of altered cardiomyocyte insulin signaling during pressure overload. Am J Physiol Heart Circ Physiol 3 (2003) H1261-H1269
16. Zhang P., Xu X., Hu X., van Deel E.D., Zhu G., and Chen Y. Inducible nitric oxide synthase deficiency protects the heart from systolic overload-induced ventricular hypertrophy and congestive heart failure. Circ Res 7 (2007) 1089-1098
17. Lu Z., Xu X., Hu X., Zhu G., Zhang P., van Deel E.D., et al. Extracellular superoxide dismutase deficiency exacerbates pressure overload-induced left ventricular hypertrophy and dysfunction. Hypertension 1 (2008) 19-25
18. Gavin A.D., and Struthers A.D. Allopurinol reduces B-type natriuretic peptide concentrations and haemoglobin but does not alter exercise capacity in chronic heart failure. Heart 6 (2005) 749-753
19. Giordano F.J. Oxygen, oxidative stress, hypoxia, and heart failure. J Clin Invest 3 (2005) 500-508
20. Zhao L., Roche B.M., Wessale J.L., Kijtawornrat A., Lolly J.L., Shemanski D., et al. Chronic xanthine oxidase inhibition following myocardial infarction in rabbits: effects of early versus delayed treatment. Life Sci 9-10 (2008) 495-502
21. van Deel E.D., Lu Z., Xu X., Zhu G., Hu X., Oury T.D., et al. Extracellular superoxide dismutase protects the heart against oxidative stress and hypertrophy after myocardial infarction. Free Radic Biol Med 7 (2008) 1305-1313
22. Takimoto E., Champion H.C., Li M., Ren S., Rodriguez E.R., Tavazzi B., et al. Oxidant stress from nitric oxide synthase-3 uncoupling stimulates cardiac pathologic remodeling from chronic pressure load. J Clin Invest 5 (2005) 1221-1231
23. Hayashi K., Kimata H., Obata K., Matsushita A., Fukata A., Hashimoto K., et al. Xanthine oxidase inhibition improves left ventricular dysfunction in dilated cardiomyopathic hamsters. J Card Fail 3 (2008) 238-244
24. Ide T., Tsutsui H., Kinugawa S., Utsumi H., Kang D., Hattori N., et al. Mitochondrial electron transport complex I is a potential source of oxygen free radicals in the failing myocardium. Circ Res 4 (1999) 357-363
25. McKelvey T.G., Hollwarth M.E., Granger D.N., Engerson T.D., Landler U., and Jones H.P. Mechanisms of conversion of xanthine dehydrogenase to xanthine oxidase in ischemic rat liver and kidney. Am J Physiol 5 Pt 1 (1988) G753-G760
26. Perez N.G., Gao W.D., and Marban E. Novel myofilament Ca2+-sensitizing property of xanthine oxidase inhibitors. Circ Res 4 (1998) 423-430
27. Bindoli A., Cavallini L., Rigobello M.P., Coassin M., and Di Lisa F. Modification of the xanthine-converting enzyme of perfused rat heart during ischemia and oxidative stress. Free Radic Biol Med 3 (1988) 163-167
28. Hille R., and Nishino T. Flavoprotein structure and mechanism. 4. Xanthine oxidase and xanthine dehydrogenase. Faseb J 11 (1995) 995-1003
29. Bueno O.F., and Molkentin J.D. Involvement of extracellular signal-regulated kinases 1/2 in cardiac hypertrophy and cell death. Circ Res 9 (2002) 776-781
30. Sano M., Fukuda K., Sato T., Kawaguchi H., Suematsu M., Matsuda S., et al. ERK and p38 MAPK, but not NF-kappaB, are critically involved in reactive oxygen species-mediated induction of IL-6 by angiotensin II in cardiac fibroblasts. Circ Res 8 (2001) 661-669
31. Tanaka K., Honda M., and Takabatake T. Redox regulation of MAPK pathways and cardiac hypertrophy in adult rat cardiac myocyte. J Am Coll Cardiol 2 (2001) 676-685
32. Matsui T., Nagoshi T., and Rosenzweig A. Akt and PI 3-kinase signaling in cardiomyocyte hypertrophy and survival. Cell Cycle 3 (2003) 220-223
33. McMullen J.R., Sherwood M.C., Tarnavski O., Zhang L., Dorfman A.L., Shioi T., et al. Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload. Circulation 24 (2004) 3050-3055
34. Ha T., Li Y., Gao X., McMullen J.R., Shioi T., Izumo S., et al. Attenuation of cardiac hypertrophy by inhibiting both mTOR and NFkappaB activation in vivo. Free Radic Biol Med 12 (2005) 1570-1580
35. Shioi T., McMullen J.R., Tarnavski O., Converso K., Sherwood M.C., Manning W.J., et al. Rapamycin attenuates load-induced cardiac hypertrophy in mice. Circulation 12 (2003) 1664-1670